FATE FY 2021 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$158M

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$56M+77.7% YoY

Gross Profit

$50M89.5% margin

Operating Income

-$217M-388.6% margin

Net Income

-$212M-379.9% margin

EPS (Diluted)

$-2.24

Cash Flow

Operating Cash Flow

-$163M

Free Cash Flow

-$214M

Stock-Based Comp.

$54M

Balance Sheet

Total Assets

$921M

Total Liabilities

$243M

Stockholders' Equity

$679M

Cash & Equivalents

$134M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$56M	$31M	+77.7%
Gross Profit	$50M	-$94M	+153.1%
Operating Income	-$217M	-$128M	-69.4%
Net Income	-$212M	-$173M	-22.4%